시장보고서
상품코드
1155433

세계의 유전 독성 시험 시장 규모, 점유율, 산업 동향 분석 보고서 : 제품별, 종류별, 용도별(의약품과 바이오테크놀러지, 식품 산업, 화장품 산업), 지역별 전망과 예측(2022-2028년)

Global Genetic Toxicology Testing Market Size, Share & Industry Trends Analysis Report By Product, By Type, By Application (Pharmaceutical & Biotechnology, Food Industry, Cosmetics Industry), By Regional Outlook and Forecast, 2022 - 2028

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 199 Pages | 배송안내 : 즉시배송

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 유전 독성 시험 시장 규모는 2028년까지 24억 달러에 달하고, 예측기간 중 CAGR 13.2%의 시장 성장률로 상승할 것으로 예측됩니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 규모
  • 세분화
    • 세계의 유전 독성 시험 시장, 제품별
    • 세계의 유전 독성 시험 시장, 종류별
    • 세계의 유전 독성 시험 시장, 용도별
    • 세계의 유전 독성 시험 시장, 지역별
  • 조사 방법

제2장 시장 개요

  • 서론
    • 개요 설명
      • 시장 구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인

제3장 유전 독성 시험 시장에서 전개되고 있는 전략

제4장 세계의 유전 독성 시험 시장 : 제품별

  • 세계의 서비스 시장 : 지역별
  • 세계의 시약·소모품 시장 : 지역별
  • 세계의 어세이 시장 : 지역별

제5장 세계의 유전 독성 시험 시장 : 종류별

  • 세계의 In Vitro 시장 : 지역별
  • 세계의 In Vivo 시장 : 지역별

제6장 세계의 유전 독성 시험 시장 : 용도별

  • 세계의 제약·바이오테크놀러지 시장 : 지역별
  • 세계의 식품 산업 시장 : 지역별
  • 세계의 화장품 업계 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제7장 세계의 유전 독성 시험 시장 : 지역별

  • 북미
    • 북미의 유전 독성 시험 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽의 유전 독성 시험 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양의 유전 독성 시험 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • LAMEA
    • LAMEA의 유전 독성 시험 시장 : 국가별
      • 브라질
      • 아르헨티나
      • UAE
      • 사우디아라비아
      • 남아프리카공화국
      • 나이지리아
      • 기타 LAMEA

제8장 기업 개요

  • Thermo Fisher Scientific, Inc.
  • Eurofins Scientific Group
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • Jubilant Pharmova Limited
  • Syngene International Limited
  • Gentronix Ltd.
  • Inotiv, Inc.
  • Creative Bioarray
  • MB Research Laboratories
KSM 22.11.28

The Global Genetic Toxicology Testing Market size is expected to reach $2.4 billion by 2028, rising at a market growth of 13.2% CAGR during the forecast period.

The genetic toxicology testing research and observes the consequences of numerous physical, biological, and chemical substances on the heredity of live creatures. Genetic toxicology is the study of the harmful outcomes of DNA damage. These examinations are carried out either to detect chromosomal damage or gene mutation.

Agrochemicals, pharmaceutical impurities, chemicals utilized in the cosmetics industry, pharmaceutical medications, and industrial chemicals are all subjected to toxicological studies. Genetic toxicology is a crucial component of research and development (R&D), where novel medications are developed and designed through a variety of studies. These tests aid in the development of novel medications and vaccinations.

These studies also concentrate on in vitro drug discovery and tailored pharmaceuticals. In addition to these applications, there is a growing need for humanized animal models, which will present a plethora of chances for the major competitors in the genetic toxicology testing market. Testing for genetic toxicity has a variety of uses in the cosmetics, food, pharmaceutical, and biotech industries.

The requirement for genetic toxicology information is predicted to increase due to the increased medication research and discovery as well as the expanding usage of pharmacogenomics. This is because it can evaluate the substances that can cause chromosomal damage or genetic alterations. A significant growth factor in the genetic toxicity testing field is also the development of facilities and the availability of funding globally.

COVID - 19 Impact Analysis

Due to lockdowns that have halted manufacturing operations and enforced travel restrictions, affecting the transit of shipments, the rapid expansion of COVID-19 has resulted in a lack of medical equipment and supplies. COVID-19 has not severely affected the availability of raw materials used in genetic toxicology, with the exception of transportation-related delays brought on by travel restrictions and labor scarcity difficulties. Toxicology research was being conducted to comprehend the virus mutation. Similar to this, many researchers used genotoxic to evaluate how well medications worked on the COVID-19 virus. Therefore, it can be said that the pandemic had a positive impact on the genetic toxicology testing market.

Market Growth Factors

Rising investments in pharmaceutical R&D by companies

By raising the adoption of substances in the preclinical phases, R&D operations primarily aim to raise the overall likelihood of acceptance of Phase I therapeutic candidates. In the initial stages of medication development, intense R&D activities are carried out to accomplish this. The necessity for genetic toxicology research is consequently increased. Before a medicine enters the pricey clinical stages, higher R&D expenditures in the early phases of drug products are also anticipated to enhance the usage of in vivo toxicity techniques.

Increasing demand for humanized methods of in vivo testing including animals

More and more biomedical research applications use humanized mice as test subjects. Professors at Yale University and the Jackson Laboratory (US) were awarded a three-year grant in 2017 to perform advanced research on humanized MISTRG models for understanding the biology of human melanoma along with identifying therapeutic targets. The Connecticut Bioscience Innovation Fund (CBIF) awarded the Jackson Laboratory and Yale University (US) a grant in the amount of USD 700,000 in November 2018. This award supported scientific collaboration to create humanized mouse models that correctly reflect how people react to disease and cancer treatments.

Market Restraining Factors

Insufficient verified in vitro models for complex endpoint research

Given that human proteins and antibodies make over half of the novel medications created, autoimmune disease and immunological activation are crucial endpoints for drug development. These medicinal compounds can only yet be tested in animal models. The use of in vitro genetic toxicology testing techniques does not permit the assessment of the response induced within a body following secondary infection. These techniques can't assess how well a body recovers in response to short-term versus long-term immunosuppression.

Product Outlook

Based on product, the genetic toxicology testing market is classified into reagents & consumables, assays, and services. The service segment procured the largest revenue share in the genetic toxicology testing market in 2021. The segment expansion is being fuelled by Contract Research Organizations' (CROs') growing strategic ambitions through investment in this sector. The rising scope of services in the epidermis and genetic toxicological testing is another factor fuelling the service sector. For instance, in order to meet the growing demand around the world, Gentronix announced that the scope of its services in the field of cutaneous toxicity will be expanding.

Type Outlook

On the basis of type, the genetic toxicology testing market is bifurcated into In Vitro and In Vivo. The in vivo segment procured a significant revenue share in the genetic toxicology testing market in 2021. An essential component of medical research generally is in vivo testing, particularly in clinical trials. Studies conducted in living organisms (in vivo) offer useful knowledge about a substance's effects or the progression of a disease. Clinical trials and animal studies are the two main categories of in vivo testing.

Application Outlook

By application, the genetic toxicology testing market is segmented into pharmaceutical & biotechnology, food industry, cosmetics industry, and other. The pharmaceutical and biotechnology segment witnessed the maximum revenue share in the genetic toxicology testing market in 2021. It is projected that one of the driving forces behind the rise will be the extensive utilization of genotoxicity testing in medicine development and research. Testing for genetic toxicity is done at the preclinical stage. Additionally, it is predicted that the biotechnology and pharmaceutical sector will increase at a fast pace as well. Given that testing is necessary for all quantities of medications and substances.

Regional Outlook

Region-wise, the genetic toxicology testing market is analysed across North America, Europe, Asia Pacific and LAMEA. The North American region witnessed the highest revenue share in the genetic toxicology testing market in 2021. The dominance in the region can be due to rising medication development and significant pipeline spending. Additionally, the presence of important actors in the region makes genotoxicology testing more accessible for local pharmaceutical and biotech firms. The significant share of this industry is due to the growth of structure-based medication designs, rising financing for life sciences research, high R&D costs in the biopharmaceutical industry, and the burgeoning uptake of cutting-edge techniques in North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific Group, Jubilant Pharmova Limited., Syngene International Limited, Gentronix Ltd., Inotiv Inc., Creative Bioarray and MB Research Laboratories.

Strategies deployed in Genetic Toxicology Testing Market

Feb-2022: Eurofins Clinical Testing Lux Sarl, a subsidiary of Eurofins Scientific acquired Genetic Testing Service, (Gentis), the market leader in specialized genetic analysis in Vietnam. With the acquisition, Eurofins focused on expanding its reach in Asia and complemented its worldwide network of clinical diagnostics laboratories working on technical and advanced genetic testing.

Jan-2022: Inotiv acquired Integrated Laboratory Systems, a portfolio company of Sier Capital Partners. Through the acquisition, Inotiv aimed to diversify the company's in vivo and in vitro toxicology services, comprising of prominent pathology and toxicology expertise. The acquisition increased the company's services into genomics, bioinformatics, and computational toxicology which further extended its market reach and created effective new cross-selling possibilities.

Sep-2021: Labcorp took over operating assets and intellectual property (IP) of the autoimmune business unit of Myriad Genetics, together with Vectra rheumatoid arthritis (RA) assay. The inclusion of Vectra testing abilities to Labcorp products' range presented the tremendous potential for the company to develop the test's availability and make Labcorp a single-source diagnostics solution for RA providers.

Aug-2021: Inotiv announced the acquisition of Gateway Pharmacology Laboratories, a preclinical contract research organization specializing in cardiovascular pharmacology studies. Following this acquisition, Inotiv augmented its array of in vivo abilities and integrated laboratory support assistance to include cardiovascular and renal pharmacology.

Jul-2021: Gentronix took over Big Blue transgenic mutation assay models by Bioreliance, the largest provider of outsourcing services focused on the rapidly growing biologics sector of the pharmaceutical industry. Through this acquisition, Gentronix aimed to double its revenues and augment its genetic toxicology capabilities in vitro skin and in vitro ocular toxicity testing.

Jun-2021: Charles River Laboratories acquired Vigene Biosciences, a premier, a gene therapy contract development and manufacturing organization. Through the acquisition, Charles River focused on augmenting its extensive cell and gene therapy range by utilizing the gene therapy expertise of Vigene Biosciences. The increased portfolio span incorporated each of the major CDMO platforms - cell therapy, viral vector, and plasmid DNA production.

Jan-2021: Charles River Laboratories partnered with Cypre, a biotechnology company that utilizes 3D hydrogel technology to advance the knowledge of the tumor microenvironment and predict therapeutic usefulness. This partnership helped the former company's clients with access to Falcon-X, Cypre's proprietary 3D tumor model platform. Moreover, the partnership broadened Charles River's 3D in vitro testing services to further optimize immuno-oncological methods for its clients.

Jan-2019: Charles River Laboratories formed an agreement with Toxys, a company that provides innovative in vitro toxicity screening solutions. Under the agreement, CRL focused on providing ToxTracker, a range of assays that enable rapid carcinogenicity toxicity hazard identification in novel and existing drugs, chemicals, and other substances in North America. The agreement equipped CRL's client base with the utilization of the ToxTracker assay that can assist in mitigating the risk of regulatory rejection by illustrating the exact mechanism of genotoxicity.

Scope of the Study

Market Segments covered in the Report:

By Product

  • Services
  • Reagents & Consumables
  • Assays

By Type

  • In Vitro
  • In Vivo

By Application

  • Pharmaceutical & Biotechnology
  • Food Industry
  • Cosmetics Industry
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific Group
  • Jubilant Pharmova Limited.
  • Syngene International Limited
  • Gentronix Ltd.
  • Inotiv Inc.
  • Creative Bioarray
  • MB Research Laboratories

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Genetic Toxicology Testing Market, by Product
    • 1.4.2 Global Genetic Toxicology Testing Market, by Type
    • 1.4.3 Global Genetic Toxicology Testing Market, by Application
    • 1.4.4 Global Genetic Toxicology Testing Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies deployed in Genetic Toxicology Testing Market

Chapter 4. Global Genetic Toxicology Testing Market by Product

  • 4.1 Global Services Market by Region
  • 4.2 Global Reagents & Consumables Market by Region
  • 4.3 Global Assays Market by Region

Chapter 5. Global Genetic Toxicology Testing Market by Type

  • 5.1 Global In Vitro Market by Region
  • 5.2 Global In Vivo Market by Region

Chapter 6. Global Genetic Toxicology Testing Market by Application

  • 6.1 Global Pharmaceutical & Biotechnology Market by Region
  • 6.2 Global Food Industry Market by Region
  • 6.3 Global Cosmetics Industry Market by Region
  • 6.4 Global Others Market by Region

Chapter 7. Global Genetic Toxicology Testing Market by Region

  • 7.1 North America Genetic Toxicology Testing Market
    • 7.1.1 North America Genetic Toxicology Testing Market by Product
      • 7.1.1.1 North America Services Market by Country
      • 7.1.1.2 North America Reagents & Consumables Market by Country
      • 7.1.1.3 North America Assays Market by Country
    • 7.1.2 North America Genetic Toxicology Testing Market by Type
      • 7.1.2.1 North America In Vitro Market by Country
      • 7.1.2.2 North America In Vivo Market by Country
    • 7.1.3 North America Genetic Toxicology Testing Market by Application
      • 7.1.3.1 North America Pharmaceutical & Biotechnology Market by Country
      • 7.1.3.2 North America Food Industry Market by Country
      • 7.1.3.3 North America Cosmetics Industry Market by Country
      • 7.1.3.4 North America Others Market by Country
    • 7.1.4 North America Genetic Toxicology Testing Market by Country
      • 7.1.4.1 US Genetic Toxicology Testing Market
        • 7.1.4.1.1 US Genetic Toxicology Testing Market by Product
        • 7.1.4.1.2 US Genetic Toxicology Testing Market by Type
        • 7.1.4.1.3 US Genetic Toxicology Testing Market by Application
      • 7.1.4.2 Canada Genetic Toxicology Testing Market
        • 7.1.4.2.1 Canada Genetic Toxicology Testing Market by Product
        • 7.1.4.2.2 Canada Genetic Toxicology Testing Market by Type
        • 7.1.4.2.3 Canada Genetic Toxicology Testing Market by Application
      • 7.1.4.3 Mexico Genetic Toxicology Testing Market
        • 7.1.4.3.1 Mexico Genetic Toxicology Testing Market by Product
        • 7.1.4.3.2 Mexico Genetic Toxicology Testing Market by Type
        • 7.1.4.3.3 Mexico Genetic Toxicology Testing Market by Application
      • 7.1.4.4 Rest of North America Genetic Toxicology Testing Market
        • 7.1.4.4.1 Rest of North America Genetic Toxicology Testing Market by Product
        • 7.1.4.4.2 Rest of North America Genetic Toxicology Testing Market by Type
        • 7.1.4.4.3 Rest of North America Genetic Toxicology Testing Market by Application
  • 7.2 Europe Genetic Toxicology Testing Market
    • 7.2.1 Europe Genetic Toxicology Testing Market by Product
      • 7.2.1.1 Europe Services Market by Country
      • 7.2.1.2 Europe Reagents & Consumables Market by Country
      • 7.2.1.3 Europe Assays Market by Country
    • 7.2.2 Europe Genetic Toxicology Testing Market by Type
      • 7.2.2.1 Europe In Vitro Market by Country
      • 7.2.2.2 Europe In Vivo Market by Country
    • 7.2.3 Europe Genetic Toxicology Testing Market by Application
      • 7.2.3.1 Europe Pharmaceutical & Biotechnology Market by Country
      • 7.2.3.2 Europe Food Industry Market by Country
      • 7.2.3.3 Europe Cosmetics Industry Market by Country
      • 7.2.3.4 Europe Others Market by Country
    • 7.2.4 Europe Genetic Toxicology Testing Market by Country
      • 7.2.4.1 Germany Genetic Toxicology Testing Market
        • 7.2.4.1.1 Germany Genetic Toxicology Testing Market by Product
        • 7.2.4.1.2 Germany Genetic Toxicology Testing Market by Type
        • 7.2.4.1.3 Germany Genetic Toxicology Testing Market by Application
      • 7.2.4.2 UK Genetic Toxicology Testing Market
        • 7.2.4.2.1 UK Genetic Toxicology Testing Market by Product
        • 7.2.4.2.2 UK Genetic Toxicology Testing Market by Type
        • 7.2.4.2.3 UK Genetic Toxicology Testing Market by Application
      • 7.2.4.3 France Genetic Toxicology Testing Market
        • 7.2.4.3.1 France Genetic Toxicology Testing Market by Product
        • 7.2.4.3.2 France Genetic Toxicology Testing Market by Type
        • 7.2.4.3.3 France Genetic Toxicology Testing Market by Application
      • 7.2.4.4 Russia Genetic Toxicology Testing Market
        • 7.2.4.4.1 Russia Genetic Toxicology Testing Market by Product
        • 7.2.4.4.2 Russia Genetic Toxicology Testing Market by Type
        • 7.2.4.4.3 Russia Genetic Toxicology Testing Market by Application
      • 7.2.4.5 Spain Genetic Toxicology Testing Market
        • 7.2.4.5.1 Spain Genetic Toxicology Testing Market by Product
        • 7.2.4.5.2 Spain Genetic Toxicology Testing Market by Type
        • 7.2.4.5.3 Spain Genetic Toxicology Testing Market by Application
      • 7.2.4.6 Italy Genetic Toxicology Testing Market
        • 7.2.4.6.1 Italy Genetic Toxicology Testing Market by Product
        • 7.2.4.6.2 Italy Genetic Toxicology Testing Market by Type
        • 7.2.4.6.3 Italy Genetic Toxicology Testing Market by Application
      • 7.2.4.7 Rest of Europe Genetic Toxicology Testing Market
        • 7.2.4.7.1 Rest of Europe Genetic Toxicology Testing Market by Product
        • 7.2.4.7.2 Rest of Europe Genetic Toxicology Testing Market by Type
        • 7.2.4.7.3 Rest of Europe Genetic Toxicology Testing Market by Application
  • 7.3 Asia Pacific Genetic Toxicology Testing Market
    • 7.3.1 Asia Pacific Genetic Toxicology Testing Market by Product
      • 7.3.1.1 Asia Pacific Services Market by Country
      • 7.3.1.2 Asia Pacific Reagents & Consumables Market by Country
      • 7.3.1.3 Asia Pacific Assays Market by Country
    • 7.3.2 Asia Pacific Genetic Toxicology Testing Market by Type
      • 7.3.2.1 Asia Pacific In Vitro Market by Country
      • 7.3.2.2 Asia Pacific In Vivo Market by Country
    • 7.3.3 Asia Pacific Genetic Toxicology Testing Market by Application
      • 7.3.3.1 Asia Pacific Pharmaceutical & Biotechnology Market by Country
      • 7.3.3.2 Asia Pacific Food Industry Market by Country
      • 7.3.3.3 Asia Pacific Cosmetics Industry Market by Country
      • 7.3.3.4 Asia Pacific Others Market by Country
    • 7.3.4 Asia Pacific Genetic Toxicology Testing Market by Country
      • 7.3.4.1 China Genetic Toxicology Testing Market
        • 7.3.4.1.1 China Genetic Toxicology Testing Market by Product
        • 7.3.4.1.2 China Genetic Toxicology Testing Market by Type
        • 7.3.4.1.3 China Genetic Toxicology Testing Market by Application
      • 7.3.4.2 Japan Genetic Toxicology Testing Market
        • 7.3.4.2.1 Japan Genetic Toxicology Testing Market by Product
        • 7.3.4.2.2 Japan Genetic Toxicology Testing Market by Type
        • 7.3.4.2.3 Japan Genetic Toxicology Testing Market by Application
      • 7.3.4.3 India Genetic Toxicology Testing Market
        • 7.3.4.3.1 India Genetic Toxicology Testing Market by Product
        • 7.3.4.3.2 India Genetic Toxicology Testing Market by Type
        • 7.3.4.3.3 India Genetic Toxicology Testing Market by Application
      • 7.3.4.4 South Korea Genetic Toxicology Testing Market
        • 7.3.4.4.1 South Korea Genetic Toxicology Testing Market by Product
        • 7.3.4.4.2 South Korea Genetic Toxicology Testing Market by Type
        • 7.3.4.4.3 South Korea Genetic Toxicology Testing Market by Application
      • 7.3.4.5 Singapore Genetic Toxicology Testing Market
        • 7.3.4.5.1 Singapore Genetic Toxicology Testing Market by Product
        • 7.3.4.5.2 Singapore Genetic Toxicology Testing Market by Type
        • 7.3.4.5.3 Singapore Genetic Toxicology Testing Market by Application
      • 7.3.4.6 Malaysia Genetic Toxicology Testing Market
        • 7.3.4.6.1 Malaysia Genetic Toxicology Testing Market by Product
        • 7.3.4.6.2 Malaysia Genetic Toxicology Testing Market by Type
        • 7.3.4.6.3 Malaysia Genetic Toxicology Testing Market by Application
      • 7.3.4.7 Rest of Asia Pacific Genetic Toxicology Testing Market
        • 7.3.4.7.1 Rest of Asia Pacific Genetic Toxicology Testing Market by Product
        • 7.3.4.7.2 Rest of Asia Pacific Genetic Toxicology Testing Market by Type
        • 7.3.4.7.3 Rest of Asia Pacific Genetic Toxicology Testing Market by Application
  • 7.4 LAMEA Genetic Toxicology Testing Market
    • 7.4.1 LAMEA Genetic Toxicology Testing Market by Product
      • 7.4.1.1 LAMEA Services Market by Country
      • 7.4.1.2 LAMEA Reagents & Consumables Market by Country
      • 7.4.1.3 LAMEA Assays Market by Country
    • 7.4.2 LAMEA Genetic Toxicology Testing Market by Type
      • 7.4.2.1 LAMEA In Vitro Market by Country
      • 7.4.2.2 LAMEA In Vivo Market by Country
    • 7.4.3 LAMEA Genetic Toxicology Testing Market by Application
      • 7.4.3.1 LAMEA Pharmaceutical & Biotechnology Market by Country
      • 7.4.3.2 LAMEA Food Industry Market by Country
      • 7.4.3.3 LAMEA Cosmetics Industry Market by Country
      • 7.4.3.4 LAMEA Others Market by Country
    • 7.4.4 LAMEA Genetic Toxicology Testing Market by Country
      • 7.4.4.1 Brazil Genetic Toxicology Testing Market
        • 7.4.4.1.1 Brazil Genetic Toxicology Testing Market by Product
        • 7.4.4.1.2 Brazil Genetic Toxicology Testing Market by Type
        • 7.4.4.1.3 Brazil Genetic Toxicology Testing Market by Application
      • 7.4.4.2 Argentina Genetic Toxicology Testing Market
        • 7.4.4.2.1 Argentina Genetic Toxicology Testing Market by Product
        • 7.4.4.2.2 Argentina Genetic Toxicology Testing Market by Type
        • 7.4.4.2.3 Argentina Genetic Toxicology Testing Market by Application
      • 7.4.4.3 UAE Genetic Toxicology Testing Market
        • 7.4.4.3.1 UAE Genetic Toxicology Testing Market by Product
        • 7.4.4.3.2 UAE Genetic Toxicology Testing Market by Type
        • 7.4.4.3.3 UAE Genetic Toxicology Testing Market by Application
      • 7.4.4.4 Saudi Arabia Genetic Toxicology Testing Market
        • 7.4.4.4.1 Saudi Arabia Genetic Toxicology Testing Market by Product
        • 7.4.4.4.2 Saudi Arabia Genetic Toxicology Testing Market by Type
        • 7.4.4.4.3 Saudi Arabia Genetic Toxicology Testing Market by Application
      • 7.4.4.5 South Africa Genetic Toxicology Testing Market
        • 7.4.4.5.1 South Africa Genetic Toxicology Testing Market by Product
        • 7.4.4.5.2 South Africa Genetic Toxicology Testing Market by Type
        • 7.4.4.5.3 South Africa Genetic Toxicology Testing Market by Application
      • 7.4.4.6 Nigeria Genetic Toxicology Testing Market
        • 7.4.4.6.1 Nigeria Genetic Toxicology Testing Market by Product
        • 7.4.4.6.2 Nigeria Genetic Toxicology Testing Market by Type
        • 7.4.4.6.3 Nigeria Genetic Toxicology Testing Market by Application
      • 7.4.4.7 Rest of LAMEA Genetic Toxicology Testing Market
        • 7.4.4.7.1 Rest of LAMEA Genetic Toxicology Testing Market by Product
        • 7.4.4.7.2 Rest of LAMEA Genetic Toxicology Testing Market by Type
        • 7.4.4.7.3 Rest of LAMEA Genetic Toxicology Testing Market by Application

Chapter 8. Company Profiles

  • 8.1 Thermo Fisher Scientific, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
  • 8.2 Eurofins Scientific Group
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Regional Analysis
    • 8.2.4 Recent strategies and developments:
      • 8.2.4.1 Acquisition and Mergers:
  • 8.3 Laboratory Corporation of America Holdings
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental Analysis
    • 8.3.4 Recent strategies and developments:
      • 8.3.4.1 Acquisition and Mergers:
  • 8.4 Charles River Laboratories International, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Recent strategies and developments:
      • 8.4.4.1 Partnerships, Collaborations, and Agreements:
      • 8.4.4.2 Acquisition and Mergers:
  • 8.5 Jubilant Pharmova Limited
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expenses
  • 8.6 Syngene International Limited
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Regional Analysis
  • 8.7 Gentronix Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Recent strategies and developments:
      • 8.7.2.1 Acquisition and Mergers:
  • 8.8 Inotiv, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expenses
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Acquisition and Mergers:
  • 8.9 Creative Bioarray
    • 8.9.1 Company Overview
  • 8.10. MB Research Laboratories
    • 8.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제